Professor John Zalcberg reacts to the QINLOCK® (ripretinib) PBS listing

ST is delighted to announce that our therapy QINLOCK® (ripretinib) was reimbursed for eligible Australian GIST patients from December 1 2021. International GIST expert Professor John Zalcberg reacts to the listing. Click for more.